MTOR and neoplasm: In a meta-analysis of 11 clinical trials, mTOR inhibitors, as single-agent therapy, failed to show a significant tumor response, and a better partial tumor response in combination with chemotherapy and/or radiotherapy needs additional evaluation to validate the sensitizing effect [34].